CHICAGO--(BUSINESS WIRE)--Investigators today presented data from a Phase 1, dose-escalation trial with ARQ 197, a selective inhibitor of the c-Met receptor tyrosine kinase under development by ArQule, Inc. (NASDAQ: ARQL). These data demonstrate that the compound is safe and well tolerated at oral doses up to 300 milligrams (mg) twice daily (b.i.d.), with dose-limiting toxicity (DLT) observed at 400 mg b.i.d. Analysis of tumor biopsy samples from patients in this trial who received from 100 mg to 300 mg of ARQ 197 b.i.d. confirms the inhibition of c-Met by ARQ 197.
